skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis

Review

(1691) Views  (421) Full article downloads

Authors: Julie A Murphy, Jacklyn A Harris, Andrew J Crannage

Published Date September 2010 Volume 2010:6(1) Pages 619 - 625
DOI: http://dx.doi.org/10.2147/NDT.S3501

Julie A Murphy, Jacklyn A Harris, Andrew J Crannage
St Louis College of Pharmacy, St Louis, MO, USA

Abstract: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. The clinical course of MS varies among patients. Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing-remitting MS. Cladribine, also known as 2-chlorodeoxyadenosine, is a synthetic adenosine deaminase-resistant purine nucleoside analog that preferentially depletes lymphocyte subpopulations. This sustained effect on lymphocytes is advantageous for patients with MS. CLARITY (CLAdRIbine Tablets Treating MS OrallY), a Phase III trial, has demonstrated that short-term oral cladribine decreases relapse rates and risk of disability progression in comparison with placebo. Cladribine was well tolerated in the study, with the most common adverse effects being headache, nausea, upper respiratory tract infections, and lymphocytopenia. An ongoing study is evaluating the efficacy and safety of the combination of oral cladribine and IFN-β products. A further ongoing study is examining the use of oral cladribine in clinically isolated syndrome and time to conversion to MS. Although the results of CLARITY are promising, the exact role of oral cladribine may be better defined with the completion of ongoing studies.

Keywords: cladribine, multiple sclerosis, relapsing-remitting, oral, disease-modifying therapy






Readers of this article also read:

Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
ABO and rhesus blood group distribution in Kurds
Brain amyloid β protein and memory disruption in Alzheimer’s disease
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Update on treatment of partial onset epilepsy: role of eslicarbazepine
Walking impairment in patients with multiple sclerosis: exercise training as a treatment option
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?